| Primary |
| Dementia Alzheimer's Type |
28.4% |
| Product Used For Unknown Indication |
24.6% |
| Hypertension |
8.6% |
| Dementia |
7.9% |
| Drug Use For Unknown Indication |
7.4% |
| Constipation |
3.6% |
| Gastrooesophageal Reflux Disease |
2.5% |
| Gastric Ulcer |
2.4% |
| Diabetes Mellitus |
2.1% |
| Osteoporosis |
2.0% |
| Hyperlipidaemia |
1.6% |
| Depression |
1.5% |
| Insomnia |
1.2% |
| Nasopharyngitis |
1.0% |
| Pain |
1.0% |
| Prophylaxis |
1.0% |
| Cognitive Disorder |
0.9% |
| Anxiety |
0.8% |
| Cardiac Failure |
0.8% |
| Anorexia |
0.8% |
|
| Vomiting |
12.4% |
| No Adverse Event |
12.0% |
| Decreased Appetite |
8.5% |
| Pneumonia |
8.1% |
| Fall |
4.7% |
| Loss Of Consciousness |
4.7% |
| Nausea |
4.7% |
| Syncope |
4.3% |
| Dizziness |
3.9% |
| Pleurothotonus |
3.9% |
| Incorrect Dose Administered |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Myoclonus |
3.5% |
| Restlessness |
3.5% |
| Tachycardia |
3.5% |
| Convulsion |
3.1% |
| Death |
3.1% |
| Hypertension |
3.1% |
| Myocardial Infarction |
3.1% |
| Pulmonary Embolism |
3.1% |
|
| Secondary |
| Dementia Alzheimer's Type |
24.1% |
| Product Used For Unknown Indication |
19.0% |
| Hypertension |
10.2% |
| Dementia |
5.8% |
| Constipation |
4.7% |
| Gastric Ulcer |
4.7% |
| Osteoporosis |
4.1% |
| Gastrooesophageal Reflux Disease |
3.7% |
| Drug Use For Unknown Indication |
3.7% |
| Nasopharyngitis |
3.5% |
| Hyperlipidaemia |
2.7% |
| Diabetes Mellitus |
2.1% |
| Pain |
1.9% |
| Prophylaxis |
1.7% |
| Insomnia |
1.7% |
| Depression |
1.3% |
| Pyrexia |
1.3% |
| Senile Dementia |
1.3% |
| Hypothyroidism |
1.2% |
| Oropharyngeal Pain |
1.2% |
|
| Decreased Appetite |
11.8% |
| Vomiting |
7.5% |
| Loss Of Consciousness |
7.0% |
| Pneumonia |
6.4% |
| Cholecystitis Acute |
5.9% |
| Blood Creatine Phosphokinase Increased |
5.3% |
| Incorrect Dose Administered |
5.3% |
| Restlessness |
5.3% |
| Gastric Ulcer |
4.8% |
| Nausea |
4.8% |
| Atrial Fibrillation |
4.3% |
| Inappropriate Schedule Of Drug Administration |
4.3% |
| Tremor |
4.3% |
| Neuroleptic Malignant Syndrome |
3.7% |
| Bradycardia |
3.2% |
| Cholelithiasis |
3.2% |
| No Adverse Event |
3.2% |
| Pulmonary Embolism |
3.2% |
| Salivary Hypersecretion |
3.2% |
| Syncope |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.0% |
| Dementia Alzheimer's Type |
13.8% |
| Hypertension |
7.0% |
| Dementia |
6.0% |
| Drug Use For Unknown Indication |
5.6% |
| Depression |
3.9% |
| Memory Impairment |
3.6% |
| Prophylaxis |
3.6% |
| Pain |
3.5% |
| Glaucoma |
2.9% |
| Blood Cholesterol |
2.8% |
| Parkinson's Disease |
2.5% |
| Blood Pressure |
2.3% |
| Hypercholesterolaemia |
2.3% |
| Rheumatoid Arthritis |
2.2% |
| Type 2 Diabetes Mellitus |
2.1% |
| Anxiety |
2.0% |
| Diabetes Mellitus |
2.0% |
| Hypothyroidism |
2.0% |
| Osteoporosis |
1.9% |
|
| Tremor |
8.6% |
| Urinary Tract Infection |
8.6% |
| Troponin Increased |
6.9% |
| Vomiting |
6.9% |
| Thrombocytopenia |
6.0% |
| Fall |
5.2% |
| Renal Failure Acute |
5.2% |
| Somnolence |
5.2% |
| Weight Decreased |
5.2% |
| Crying |
4.3% |
| Death |
4.3% |
| Diverticulitis |
4.3% |
| Hallucination |
4.3% |
| Hypotension |
4.3% |
| Acute Generalised Exanthematous Pustulosis |
3.4% |
| Disorientation |
3.4% |
| Dysphagia |
3.4% |
| Gastrointestinal Haemorrhage |
3.4% |
| General Physical Health Deterioration |
3.4% |
| Hemiparesis |
3.4% |
|
| Interacting |
| Dementia |
52.4% |
| Product Used For Unknown Indication |
26.2% |
| Essential Hypertension |
4.8% |
| Anticoagulant Therapy |
2.4% |
| Cognitive Disorder |
2.4% |
| Dementia Alzheimer's Type |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Insomnia |
2.4% |
| Respiratory Tract Infection |
2.4% |
| Sleep Phase Rhythm Disturbance |
2.4% |
|
| Drug Interaction |
44.4% |
| Death |
11.1% |
| International Normalised Ratio Increased |
11.1% |
| Renal Failure |
11.1% |
| Sinus Bradycardia |
11.1% |
| Withdrawal Syndrome |
11.1% |
|
